Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 2/2008

01-02-2008 | Original Paper

Omeprazole Inhibits Natural Killer Cell Functions

Authors: Huseyin Alkim, Selahattin Unal, Hamza Okur, Turgut Imir

Published in: Digestive Diseases and Sciences | Issue 2/2008

Login to get access

Abstract

This study was designed to determine the possible effects of omeprazole on human natural killer cells. Peripheral venous blood samples were taken from 20 peptic ulcer patients before and at the 14th and the 28th days of omeprazole treatment. Mononuclear cells were removed from blood and their capability of making conjugation with K562 target cells and lysing K562 target cells was evaluated. A significant decrease was found (P < 0.001) in the 14th and the 28th days compared with the basal value of the capability of the mononuclear cells to conjugate with the K562 target cells and to lyse them. This study demonstrated that omeprazole significantly reduces natural killer cell functions. This finding suggests that omeprazole may also have some effects on the other systems in addition to parietal cell acid secretion.
Literature
1.
Clissold SP, Campoli-Richards DM (1986) Omeprazole: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in peptic ulcer disease and Zollinger-Ellison Syndrome. Drugs 32:15–47PubMedCrossRef
2.
Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, Sjostrand SE, Wallmark B (1981) Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+–K+) ATPase. Nature 290:159–161PubMedCrossRef
3.
Fryklund I, Gedda K, Wallmark B (1988) Specific labelling of gastric H+, K+ ATPase by omeprazole. Biochem Pharmacol 37:2543–2549PubMedCrossRef
4.
Keeling DJ, Fallowfield C, Underwood AH (1987) The specificity of omeprazole as an (H+–K+)-ATPase inhibitor depends upon the means of its activation. Biochem Pharmacol 36:339–344PubMedCrossRef
5.
Sachs G, Wallmark B (1989) The gastric H+,K+-ATPase: the site of action of omeprazole. Scand J Gastroenterol 24(Suppl 166):3–11CrossRef
6.
7.
8.
Mellman I, Fuchs R, Helenius A (1986) Acidification of the endocytic and exocytic pathways. Ann Rev Biochem 55:663–700PubMedCrossRef
9.
Wandall JH (1992) Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation and translocation of cytochrome b-245. Gut 33:617–621PubMedCrossRef
10.
Aybay C, Imir T, Okur H (1995) The effect of omeprazole on human natural killer cell activity. Gen Pharmacol 26:1413–1418PubMed
11.
Timonen T, Ortaldo JR, Herberman RB (1981) Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med 153:569–582PubMedCrossRef
12.
Imir T, Sibbitt W, Bankhurst A (1987) The relative resistance of lymphokine activated killer cells to suppression by prostaglandins and glucocorticoids. Prostaglandins Leukotriens Med 28:111–118CrossRef
13.
Bankhurst AD, Imir T (1989) The mechanism involved in the activation of human natural killer cells by Staphylococcal Enterotoxin B. Cell Immunol 122:108–121PubMedCrossRef
14.
Ullberg M, Jondal M (1981) Recycling and target binding capacity of human natural killer cells. J Exp Med 153:615–628PubMedCrossRef
15.
Scaringi L, Cornacchione P, Fettucciari K, Rosati E, Rossi R, Marconi P, Capadicosa E (1996) Activity inhibition of cytolytic lymphocytes by omeprazole. Scand J Immunol 44:204–214PubMedCrossRef
16.
Capodicasa E, De Bellis F, Pelli MA (1999) Effect of lansoprazole on human leukocyte function. Immunopharmacol Immunotoxicol 21:357–377PubMedCrossRef
17.
Shamburek RD, Ruddy S, Schubert ML (1993) Omeprazole and neutrophil function. Gastroenterology 104:938–940PubMed
18.
Mc Tavish D, Buckley MM-T, Heel RC (1991) Omeprazole, an updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 42:138–170
19.
Lindberg P, Nordberg P, Alminger T, Brandstrom A, Wallmark B (1986) The mechanism of action of the gastric acid secretion inhibitor omeprazole. J Med Chem 29:1327–1329PubMedCrossRef
20.
Verhoef J, Sharma SD (1983) Inhibition of human natural killer activity by lysosomotropic agents. J Immunol 131:125–131PubMed
21.
22.
Deem RL, Targan SR (1984) Evidence of a dynamic role of the target cell membrane during the early stages of the Natural Killer cell lethal hit. J Immunol 133:72–77PubMed
23.
Suzuki M, Mori M, Miura S, Suematsu M, Fukumura D, Kimura H, Ishii H (1996) Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med 21:727–731PubMedCrossRef
24.
Suzuki M, Nakamura M, Mori M, Miura S, Tsuchiya M, Ishii H (1995) Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J Clin Gastroenterol 20(Suppl 2):S93–S96PubMedCrossRef
25.
Suzuki M, Mori M, Fukumura D, Suzuki H, Miura S, Ishii H (1999) Omeprazole attenuates neutrophil-endothelial cell adhesive interaction induced by extracts of Helicobacter pylori. J Gastroenterol Hepatol 14:27–31PubMedCrossRef
26.
Suzuki H, Miyazawa M, Nagahashi S, Sato M, Bessho M, Nagata H, Miura S, Ishii H (2003) Rabeprazole treatment attenuated Helicobacter pylori-associated gastric mucosal lesion formation in Mongolian gerbils. J Gastroenterol Hepatol 18:787–795PubMedCrossRef
27.
Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, Kondo M (2000) A new mechanism for anti-inflammatory actions of proton pump inhibitors – inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 14(Suppl 1):74–81PubMedCrossRef
28.
Valori RM, Cockal R (1990) Omeprazole for duodenal ulceration in Crohn’s Disease. Br Med J 300:438–439CrossRef
Metadata
Title
Omeprazole Inhibits Natural Killer Cell Functions
Authors
Huseyin Alkim
Selahattin Unal
Hamza Okur
Turgut Imir
Publication date
01-02-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9869-2

Other articles of this Issue 2/2008

Digestive Diseases and Sciences 2/2008 Go to the issue

Original Paper

Analysis of the NOD2/CARD15 Gene in Patients Affected with the Aseptic Abscesses Syndrome with or without Inflammatory Bowel Disease

Original Paper

Tanshinone IIA Ameliorates Trinitrobenzene Sulfonic Acid (TNBS)-Induced Murine Colitis

Original Paper

Prevalence of Macrocreatinkinase Type 1 in Patients with Inflammatory Bowel Disease

Original Paper

HLA DRB1*13 as a Risk Factor for Type 1 Autoimmune Hepatitis in North American Patients

Review Article

The Pathogenic Mechanism of Severe Acute Pancreatitis Complicated with Renal Injury: A Review of Current Knowledge

Original Paper

Detection of Duodenal Ulcer-Associated Genes in Rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits